89bio’s FGF21 Analog May Offer Fibrosis Benefit In Cirrhotic NASH Patients
At AASLD, 89bio presented subgroup analysis from its successful Phase IIb NASH study indicating that the drug may meaningfully reduce fibrosis even in the sickest patients, those with cirrhosis.
You may also be interested in...
Inventiva’s pan-PPAR agonist and Terns’ combination strategy are targeting the NASH treatment paradigm after expected approval of Madrigal’s resmetirom. Viking is hoping to prove a better THRβ drug profile than Madrigal.
Already prepping Phase III trials of efruxifermin in pre-cirrhotic NASH patients, Akero says it will go ahead with Phase III plans in cirrhotic patients despite missing the fibrosis endpoint in a Phase IIb trial.
89bio’s pegozafermin met co-primary endpoints of fibrosis reduction and NASH resolution in Phase IIb; the company said its methodology yielded lower placebo responses than in Akero’s Phase IIb study.